Annual SG&A
$12.75 M
-$711.00 K-5.28%
31 December 2023
Summary:
Oncternal Therapeutics annual selling, general & administrative expenses is currently $12.75 million, with the most recent change of -$711.00 thousand (-5.28%) on 31 December 2023. During the last 3 years, it has risen by +$4.37 million (+52.23%). ONCT annual SG&A is now -54.11% below its all-time high of $27.78 million, reached on 31 December 2009.ONCT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$2.73 M
-$325.00 K-10.65%
30 September 2024
Summary:
Oncternal Therapeutics quarterly selling, general & administrative expenses is currently $2.73 million, with the most recent change of -$325.00 thousand (-10.65%) on 30 September 2024. Over the past year, it has dropped by -$367.00 thousand (-11.86%). ONCT quarterly SG&A is now -65.92% below its all-time high of $8.00 million, reached on 30 September 2009.ONCT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$841.86 M
-$34.58 M-4.28%
30 September 2024
Summary:
Oncternal Therapeutics TTM selling, general & administrative expenses is currently -$841.86 million, with the most recent change of -$34.58 million (-4.28%) on 30 September 2024. Over the past year, it has dropped by -$854.63 million (-6691.98%). ONCT TTM SG&A is now -454.76% below its all-time high of $27.82 million, reached on 30 September 2009.ONCT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ONCT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.3% | -11.9% | -6692.0% |
| 3 y3 years | +52.2% | -2.7% | -8163.8% |
| 5 y5 years | +35.7% | +14.3% | -8640.8% |
ONCT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -5.3% | +52.2% | -25.9% | +4.2% | -125.1% | at low |
| 5 y | 5 years | -5.3% | +74.9% | -25.9% | +86.4% | -231.7% | +36.4% |
| alltime | all time | -54.1% | +4878.9% | -65.9% | +827.5% | -454.8% | +64.7% |
Oncternal Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.73 M(-10.6%) | $12.33 M(-2.9%) |
| June 2024 | - | $3.05 M(-7.2%) | $12.70 M(-0.2%) |
| Mar 2024 | - | $3.29 M(+0.8%) | $12.72 M(-0.2%) |
| Dec 2023 | $12.75 M(-5.3%) | $3.26 M(+5.5%) | $12.75 M(-0.2%) |
| Sept 2023 | - | $3.09 M(+0.7%) | $12.77 M(-1.3%) |
| June 2023 | - | $3.07 M(-7.3%) | $12.94 M(-1.2%) |
| Mar 2023 | - | $3.31 M(+0.8%) | $13.09 M(-2.7%) |
| Dec 2022 | $13.46 M(+16.1%) | $3.29 M(+0.7%) | $13.46 M(+5.2%) |
| Sept 2022 | - | $3.27 M(+1.2%) | $12.79 M(+3.8%) |
| June 2022 | - | $3.23 M(-12.3%) | $12.32 M(-1.3%) |
| Mar 2022 | - | $3.68 M(+40.5%) | $12.48 M(+7.6%) |
| Dec 2021 | $11.60 M(+38.5%) | $2.62 M(-6.6%) | $11.60 M(+11.1%) |
| Sept 2021 | - | $2.80 M(-17.1%) | $10.44 M(+9.1%) |
| June 2021 | - | $3.38 M(+21.0%) | $9.57 M(+12.2%) |
| Mar 2021 | - | $2.79 M(+91.0%) | $8.53 M(+1.9%) |
| Dec 2020 | $8.37 M(+14.9%) | $1.46 M(-24.3%) | $8.37 M(-9.6%) |
| Sept 2020 | - | $1.93 M(-17.5%) | $9.26 M(-4.7%) |
| June 2020 | - | $2.34 M(-11.0%) | $9.71 M(+8.1%) |
| Mar 2020 | - | $2.63 M(+12.1%) | $8.99 M(-8.9%) |
| Dec 2019 | $7.29 M(-22.4%) | $2.35 M(-1.5%) | $9.86 M(+0.0%) |
| Sept 2019 | - | $2.38 M(+47.3%) | $9.86 M(+2.3%) |
| June 2019 | - | $1.62 M(-53.8%) | $9.63 M(-5.7%) |
| Mar 2019 | - | $3.51 M(+49.5%) | $10.21 M(+8.7%) |
| Dec 2018 | $9.39 M(+2.2%) | $2.35 M(+8.6%) | $9.39 M(-1.5%) |
| Sept 2018 | - | $2.16 M(-1.6%) | $9.53 M(-4.6%) |
| June 2018 | - | $2.20 M(-18.3%) | $9.99 M(+2.0%) |
| Mar 2018 | - | $2.69 M(+8.1%) | $9.79 M(+6.5%) |
| Dec 2017 | $9.19 M(+5.5%) | $2.49 M(-5.0%) | $9.19 M(+2.3%) |
| Sept 2017 | - | $2.62 M(+31.0%) | $8.98 M(+3.5%) |
| June 2017 | - | $2.00 M(-4.3%) | $8.68 M(-0.0%) |
| Mar 2017 | - | $2.09 M(-8.4%) | $8.68 M(-0.3%) |
| Dec 2016 | $8.71 M(+5.7%) | $2.28 M(-1.5%) | $8.71 M(+2.4%) |
| Sept 2016 | - | $2.31 M(+15.7%) | $8.51 M(+3.3%) |
| June 2016 | - | $2.00 M(-5.4%) | $8.23 M(-0.1%) |
| Mar 2016 | - | $2.11 M(+1.7%) | $8.24 M(+0.0%) |
| Dec 2015 | $8.23 M(-13.1%) | $2.08 M(+2.0%) | $8.23 M(-1.5%) |
| Sept 2015 | - | $2.04 M(+1.7%) | $8.36 M(+5.6%) |
| June 2015 | - | $2.00 M(-5.0%) | $7.91 M(-11.7%) |
| Mar 2015 | - | $2.11 M(-4.2%) | $8.96 M(-5.5%) |
| Dec 2014 | $9.48 M(-16.0%) | $2.20 M(+38.2%) | $9.48 M(-8.6%) |
| Sept 2014 | - | $1.59 M(-47.8%) | $10.37 M(-7.9%) |
| June 2014 | - | $3.05 M(+16.1%) | $11.26 M(+3.4%) |
| Mar 2014 | - | $2.63 M(-14.9%) | $10.89 M(-3.5%) |
| Dec 2013 | $11.28 M | $3.09 M(+24.5%) | $11.28 M(+2.1%) |
| Sept 2013 | - | $2.48 M(-7.5%) | $11.05 M(-4.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | $2.68 M(-11.2%) | $11.56 M(+2.5%) |
| Mar 2013 | - | $3.02 M(+5.8%) | $11.28 M(+4.0%) |
| Dec 2012 | $10.85 M(-9.8%) | $2.86 M(-4.7%) | $10.85 M(-2.5%) |
| Sept 2012 | - | $3.00 M(+25.0%) | $11.13 M(+2.7%) |
| June 2012 | - | $2.40 M(-7.3%) | $10.84 M(-16.0%) |
| Mar 2012 | - | $2.59 M(-17.6%) | $12.91 M(-14.0%) |
| Dec 2011 | $12.03 M(-8.8%) | $3.14 M(+16.0%) | $15.00 M(+23.4%) |
| Sept 2011 | - | $2.71 M(-39.4%) | $12.16 M(-10.0%) |
| June 2011 | - | $4.47 M(-4.6%) | $13.51 M(+1.1%) |
| Mar 2011 | - | $4.68 M(+1493.2%) | $13.37 M(+1.3%) |
| Dec 2010 | $13.19 M(-52.5%) | $294.00 K(-92.8%) | $13.19 M(-31.2%) |
| Sept 2010 | - | $4.07 M(-6.0%) | $19.18 M(-17.0%) |
| June 2010 | - | $4.33 M(-4.1%) | $23.12 M(-10.3%) |
| Mar 2010 | - | $4.51 M(-28.2%) | $25.78 M(-7.2%) |
| Dec 2009 | $27.78 M(+20.2%) | $6.28 M(-21.5%) | $27.78 M(-0.1%) |
| Sept 2009 | - | $8.00 M(+14.6%) | $27.82 M(+7.3%) |
| June 2009 | - | $6.98 M(+7.2%) | $25.92 M(+2.2%) |
| Mar 2009 | - | $6.51 M(+3.0%) | $25.37 M(+9.8%) |
| Dec 2008 | $23.11 M(+71.1%) | $6.32 M(+3.6%) | $23.11 M(+13.4%) |
| Sept 2008 | - | $6.11 M(-4.9%) | $20.37 M(+16.8%) |
| June 2008 | - | $6.42 M(+51.2%) | $17.45 M(+19.2%) |
| Mar 2008 | - | $4.25 M(+18.3%) | $14.63 M(+8.4%) |
| Dec 2007 | $13.50 M(+18.9%) | $3.59 M(+12.9%) | $13.50 M(+5.9%) |
| Sept 2007 | - | $3.18 M(-11.8%) | $12.75 M(+2.5%) |
| June 2007 | - | $3.61 M(+15.8%) | $12.44 M(+8.0%) |
| Mar 2007 | - | $3.12 M(+9.6%) | $11.52 M(+1.5%) |
| Dec 2006 | $11.35 M(+15.3%) | $2.84 M(-0.8%) | $11.35 M(+3.9%) |
| Sept 2006 | - | $2.87 M(+6.5%) | $10.92 M(+5.8%) |
| June 2006 | - | $2.69 M(-8.7%) | $10.32 M(+0.5%) |
| Mar 2006 | - | $2.95 M(+22.3%) | $10.28 M(+4.4%) |
| Dec 2005 | $9.85 M(+36.5%) | $2.41 M(+6.2%) | $9.85 M(+2.2%) |
| Sept 2005 | - | $2.27 M(-14.0%) | $9.63 M(+5.1%) |
| June 2005 | - | $2.64 M(+4.8%) | $9.16 M(+13.0%) |
| Mar 2005 | - | $2.52 M(+14.7%) | $8.10 M(+12.6%) |
| Dec 2004 | $7.21 M(+102.6%) | $2.20 M(+22.0%) | $7.20 M(+15.7%) |
| Sept 2004 | - | $1.80 M(+13.6%) | $6.22 M(+16.3%) |
| June 2004 | - | $1.58 M(-1.7%) | $5.34 M(+17.2%) |
| Mar 2004 | - | $1.61 M(+32.1%) | $4.56 M(+28.2%) |
| Dec 2003 | $3.56 M(+48.0%) | $1.22 M(+31.5%) | $3.56 M(+52.2%) |
| Sept 2003 | - | $928.00 K(+15.9%) | $2.34 M(+65.8%) |
| June 2003 | - | $801.00 K(+31.3%) | $1.41 M(+131.3%) |
| Mar 2003 | - | $610.00 K | $610.00 K |
| Dec 2002 | $2.40 M(+8.1%) | - | - |
| Dec 2001 | $2.23 M(+85.0%) | - | - |
| Dec 2000 | $1.20 M(+369.9%) | - | - |
| Dec 1999 | $256.00 K | - | - |
FAQ
- What is Oncternal Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual SG&A year-on-year change?
- What is Oncternal Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly SG&A year-on-year change?
- What is Oncternal Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Oncternal Therapeutics?
- What is Oncternal Therapeutics TTM SG&A year-on-year change?
What is Oncternal Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of ONCT is $12.75 M
What is the all time high annual SG&A for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual selling, general & administrative expenses is $27.78 M
What is Oncternal Therapeutics annual SG&A year-on-year change?
Over the past year, ONCT annual selling, general & administrative expenses has changed by -$711.00 K (-5.28%)
What is Oncternal Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of ONCT is $2.73 M
What is the all time high quarterly SG&A for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly selling, general & administrative expenses is $8.00 M
What is Oncternal Therapeutics quarterly SG&A year-on-year change?
Over the past year, ONCT quarterly selling, general & administrative expenses has changed by -$367.00 K (-11.86%)
What is Oncternal Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of ONCT is -$841.86 M
What is the all time high TTM SG&A for Oncternal Therapeutics?
Oncternal Therapeutics all-time high TTM selling, general & administrative expenses is $27.82 M
What is Oncternal Therapeutics TTM SG&A year-on-year change?
Over the past year, ONCT TTM selling, general & administrative expenses has changed by -$854.63 M (-6691.98%)